Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
Author:
Affiliation:
1. Jerome Lipper Multiple Myeloma Center, Division of Hematologic Neoplasia, Harvard Medical School, and Dana-Farber Cancer Institute, Boston, MA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2005.03.8851
Reference26 articles.
1. Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
3. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
4. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
5. VAD-based regimens as primary treatment for multiple myeloma
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12
2. Response and Survival Estimates of Patients With Plasma Cell Myeloma in a Resource-Constrained Setting Using Protocols From High-Income Countries: A Single-Center Experience From Sri Lanka;JCO Global Oncology;2022-06
3. Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing;Medical Sciences;2022-02-18
4. Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up;JCO Global Oncology;2021-07
5. Overcoming cancer therapeutic bottleneck by drug repurposing;Signal Transduction and Targeted Therapy;2020-07-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3